Химиотерапия в лечении больных метастатическим раком предстательной железы: современное состояние проблемы
https://doi.org/10.17650/1726-9776-2015-11-3-108-116
Аннотация
В статье приведен обзор современных возможностей цитостатической химиотерапии у больных метастатическим раком предстательной железы. Представлены данные исследований по раннему назначению доцетаксела у больных с гормонально чувствительными опухолями, проанализированы подходы к последовательной терапии доцетакселом, кабазитакселом и антиандрогенными препаратами (абиратерон, энзалутамид) у больных кастрационно-резистентным раком предстательной железы. На основании оценки прогностической роли различных клинических и биологических факторов представлен алгоритм выбора терапии 1-й и 2-й линии у пациентов с кастрационной резистентностью.
Об авторе
Б. Я. Алексеев
НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России; Россия, 105425, Москва, ул. 3-я Парковая, 51
Россия
Россия
Список литературы
1. Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Status of cancer care for people of Russia in 2014. By eds.: A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2014. (In Russ.)].
2. Злокачественные новообразования в России в 2013 году: заболеваемость и смертность. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013: morbidity and mortality. By eds.: A.D. Caprin, V.V. Starinskiy, G.V. Petrova. Moscow, 2015. (In Russ.)].
3. Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941:385–402.
4. Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study №. 5. Scand J Urol Nephrol 2008;42(3):220–9.
5. Klotz L., McNeill I., Fleshner N. A phase 1–2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161(1):169–72.
6. Moffat LE. Comparison of Zoladex, diethylstilboestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18(Suppl 3):26–7.
7. Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002;60 (3 Suppl 1):64–71.
8. Nair B., Wilt T., MacDonald R., Rutks I. Cochrane Database Syst Rev. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. 2002;(1):CD003506.
9. Wu J.N., Fish K.M., Evans C.P. et al. No improvements noted in overall or causespecific survival in patients presented with metastatic prostate cancer over a 20-year period. Cancer 2014;120:818–23.
10. Glass T.R., Tangen C.M., Crawford E.D. et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169(1):164–9.
11. Zong Y., Goldstein A.S. Adaptation or selection – mechanisms of castrationresistant prostate cancer. Nature Review Urology 2013;10:90–8.
12. Millikan R.E., Wen S., Pagliaro L.C. et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008;26:5936–42.
13. Berthold D.R., Pond G.R., Soban F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study. J Clin Oncol 2008;26:242–5.
14. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase III trial. Lancet Oncol 2013;14(2):149–58.
15. Sweeney C.J. , Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate. Cancer N Engl J Med 2015;373:737–46.
16. James N.D., Sydes M.R., Mason M.D. et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). 2010 ASCO Annual Meeting. Abstr. 4517.
17. Parker C., Gillessen S., Heidenreich A., Horwich A. Cancer of the prostate: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 00: 1–9, 2015 doi:10.1093/annonc/mdv222.
18. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
19. Rathkopf D.E., Smith M.R., de Bono J.S. et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014;66(5): 815–25.
20. Beer T.M., Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33.
21. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castrationresistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983–92.
22. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97.
23. de Bono J.S., Logothetis C.J., Molino A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Eng J Med 2011;364:1995–2005.
24. Ryan C.J. Clinical trial design strategies in the post-abiraterone/enzalutamide setting. 2013. ASCO Genitourinary Cancers Symposium: a transformatic multidisciplinary approach, Orlando, Florida. Proceedings, Educational Summaries. Рp.26–8.
25. Rathkopf D.E., Scher H.I. Androgen receptor antagonists in castration resistant prostate cancer. Cancer Journal 2013;19(1):43–9.
26. Nakabayashi M., Hayes J., Taplin M.E. et al. Clinical predictors of survival in men with castration-resistant prostate cancer. Clin Genitourin Cancer 2011;9(2):95–103.
27. Loriot Y., Eymard J.C., Patrikidou A. Prior long response to androgen deprivation redicts
28. response to next-generation androgen receptor axis targeted drugs in castration resistant rostate cancer. Eur J Cancer 2015;51(14):1946–52.
29. Azad A.A., Eigl B.J., Leibowitz-Amit R. et al. Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. Eur Urol 2015;67(3):441–7.
30. Mostaghel E.A., Lin D.W. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol 2014;21 (2 Supp 1):57–63.
31. Mottet N., Bellmunt J., Briers E. et al. Guidelines on prostate cancer. European Association of Urology, March 2015 Update. 31. Armstrong A.J., Eisenberger M.A., Halabi S. et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate. Сancer Eur Urol 2012;61(3):549–59.
32. Antonarakis E.S., Lu C., Wang H. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028–38.
33. Antonarakis E.S., Lu C., Luber B. et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. doi:10.1001/jamaoncol.2015.1341.
34. Sanofi-Aventis. Jevtana prescribing information. June 17, 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf. Accessed February 2, 2011.
35. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253–65.
36. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92(16):1295–302.
37. Kingston D.G. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72(3):507–15.
38. Channing J. Paller, Emmanuel S. Antonarakis. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Dev Ther 2011;5:117–24.
39. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.. Lancet 2010;376(9747):1147–54.
40. Sartor A.O., Oudard S., Ozguroglu M. et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castra- tionresistant prostate cancer (mCRPC) enrolled in the TROPIC trial [abstract 4525]. J Clin Oncol 2011;29(Suppl).
41. Aapro M.S., Bohlius J., Cameron D.A. et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47(1):8–32. doi:10.1016/j.ejca.2010.10.013.
42. Smith T.J., Khatcheressian J., Lyman G.H. et al. 2006 update of recommendations for the se of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24(19):3187–205.
43. Birtle A. Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint. Expert Rev Anticancer Ther 2013;13(1):89–99; doi: 10.1586/era.12.160.
44. Afshar M., Al-Alloosh F., Pirrie S. et al. Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Res 2015;35(2):1057–63.
45. Azria D., Massard C., Tosi D. et al. An ambispective observational study evaluating safety and efficacy of abiraterone acetate in the French Temporary Authorizations for Use (ATU): Predictive parameters of response. ASCO Genitourinary Cancer Symposium 2012:B149.
46. Chi K.N., Kheoh T.C., Ryan C.J. et al. A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. J Clin Oncol 2013;31(suppl; abstr. 5013.
47. Oudard S., Mercier F., Flechon A. et al. Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2013;31(Suppl 6):abstr. 137.
48. Rescigno R., Lorente D., Ferraldeschi R. et al. Association between PSA declines at 4 weeks and overall survival (OS) in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel. Poster presented at 2015 ASCO Genitourinary Cancers Symposium: Integrating biology into patient-centric care, February 26–28, 2015, abstr. 215.
49. Sonpavde G., Bhor M., Hennessy D. et al. After docetaxel in metastatic castrationresistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Canc 2015;13(4):309–18.
50. Oudard S., Angelergues A., Gonzalez Maeso I. et al. Prognostic factors for survival and sequencing of life extending therapies in mCRPC patients in post-docetaxel setting. ESMO 2014, abstr., p. 789.
Рецензия
Для цитирования:
Алексеев Б.Я. Химиотерапия в лечении больных метастатическим раком предстательной железы: современное состояние проблемы. Онкоурология. 2015;11(3):108-116. https://doi.org/10.17650/1726-9776-2015-11-3-108-116
For citation:
Alekseev B.Y. Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem. Cancer Urology. 2015;11(3):108-116. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-3-108-116
Просмотров: 1066
Послать статью по эл. почте 
